Gustavo Pesquin - 06 Sep 2022 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Title: Executive Vice President, Chief Commercial Officer - Specialty
Signature
/s/ Jason B. Daly, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
06 Sep 2022
Net transactions value
$0
Form type
4
Filing time
08 Sep 2022, 16:19:11 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Award $0 +444,444 $0.000000 444,444 06 Sep 2022 Class A Common Stock 444,444 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 The restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Title: Executive Vice President, Chief Commercial Officer - Specialty